{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:50:29Z","timestamp":1778190629726,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ajo.2015.01.026","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T23:41:51Z","timestamp":1422402111000},"page":"980-985.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Ocular Hypotensive Safety and Systemic Absorption of AR-13324 Ophthalmic Solution in Normal Volunteers"],"prefix":"10.1016","volume":"159","author":[{"given":"Brian","family":"Levy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary D.","family":"Novack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Kopczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2015.01.026_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2015.01.026_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2015.01.026_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2015.01.026_bib4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2015.01.026_bib5","series-title":"Preferred Practice Pattern: Primary Open-Angle Glaucoma","author":"American Academy of Ophthalmology Glaucoma Panel","year":"2010"},{"key":"10.1016\/j.ajo.2015.01.026_bib6","series-title":"Preferred Practice Pattern: Primary Open-Angle Glaucoma Suspect","author":"American Academy of Ophthalmology Glaucoma Panel","year":"2010"},{"key":"10.1016\/j.ajo.2015.01.026_bib7","series-title":"Terminology and Guidelines for Glaucoma","year":"2014"},{"issue":"7","key":"10.1016\/j.ajo.2015.01.026_bib8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jamaophthalmol.2014.856","article-title":"Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the Automated Dosing Reminder Study","volume":"132","author":"Boland","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2015.01.026_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"2\u20133","key":"10.1016\/j.ajo.2015.01.026_bib10","first-page":"85","article-title":"Emerging trabecular outflow drugs","volume":"30","author":"Kopczynski","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2015.01.026_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.exer.2004.09.002","article-title":"Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys","volume":"80","author":"Tian","year":"2005","journal-title":"Exp Eye Res"},{"issue":"7","key":"10.1016\/j.ajo.2015.01.026_bib12","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","article-title":"Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys","volume":"48","author":"Tokushige","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2015.01.026_bib13","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archopht.119.8.1171","article-title":"Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes","volume":"119","author":"Honjo","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2015.01.026_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","article-title":"AR-12286 Phase2a Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension","volume":"152","author":"Williams","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2015.01.026_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/bjophthalmol-2012-302466","article-title":"Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers","volume":"97","author":"Kopczynski","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2015.01.026_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/112067210001000201","article-title":"A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol","volume":"10","author":"Hedman","year":"2000","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2015.01.026_bib17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1755-3768.2009.01852.x","article-title":"Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial","volume":"89","author":"Heijl","year":"2011","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2015.01.026_bib18","first-page":"166","article-title":"Power estimates in designing glaucoma trials","volume":"11","author":"Novack","year":"1989","journal-title":"Glaucoma"},{"issue":"1","key":"10.1016\/j.ajo.2015.01.026_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","article-title":"Effect of 0.04% AR-13324, a ROCK and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes","volume":"24","author":"Wang","year":"2015","journal-title":"J Glaucoma"},{"issue":"6654","key":"10.1016\/j.ajo.2015.01.026_bib20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension","volume":"389","author":"Uehata","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ajo.2015.01.026_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 vs. latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2015.01.026_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","article-title":"Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers","volume":"126","author":"Tanihara","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2015.01.026_bib23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2015.01.026_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0002-9394(00)00401-3","article-title":"Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye","volume":"130","author":"Sponsel","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2015.01.026_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0420.1997.tb00401.x","article-title":"Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes","volume":"75","author":"Linden","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"10.1016\/j.ajo.2015.01.026_bib26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ophtha.2007.07.002","article-title":"Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study","volume":"115","author":"Lim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2015.01.026_bib27","unstructured":"Kiel JW, Kopczynski C. Effect of AR-13324 on episcleral venous pressure (EVP) in Dutch Belted rabbits. J Ocul Pharmacol Ther. In press."},{"issue":"3","key":"10.1016\/j.ajo.2015.01.026_bib28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.exer.2003.07.002","article-title":"Goldmann's equation and clinical measures of aqueous dynamics","volume":"78","author":"Brubaker","year":"2004","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.ajo.2015.01.026_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF00143664","article-title":"Out-flow pressure, minute volume and resistance of the anterior chamber flow in man","volume":"5\u20136","author":"Goldmann","year":"1951","journal-title":"Doc Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2015.01.026_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000088378","article-title":"Episcleral venous pressure in untreated primary open-angle and normal-tension glaucoma","volume":"219","author":"Selbach","year":"2005","journal-title":"Ophthalmologica"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939415000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939415000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:13:57Z","timestamp":1757596437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939415000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0002939415000550"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2015.01.026","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Hypotensive Safety and Systemic Absorption of AR-13324 Ophthalmic Solution in Normal Volunteers","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2015.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}